Format

Send to

Choose Destination
Bioorg Med Chem. 2019 Jul 1;27(13):2718-2728. doi: 10.1016/j.bmc.2019.05.018. Epub 2019 May 13.

Eicosanoid mediation of cannabinoid actions.

Author information

1
Department of Biochemistry & Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA 01605, United States. Electronic address: sumner.burstein@umassmed.edu.

Abstract

Interactions between cannabinoids and eicosanoids have been observed for the last several decades and account for a variety of cannabinoid actions. These were seen both in vitro and in vivo and may provide a molecular basis for these actions. Some of the topics included in this review are; effects on adenylate cyclase activity, alteration of behavioral responses, reduction of pain sensation, reduction and resolution of inflammation, hypotensive and vasorelaxant responses, anti-cancer and anti-metastatic activities, reduction of intraocular pressure and others. The most widely studied cannabinoids so far are tetrahydrocannabinol and cannabidiol. However, synthetic agents such as CP55,940, ajulemic acid, JWH-133 and WIN-55,212-2 were also investigated for interaction with eicosanoids. The endocannabinoids anandamide and 2-arachidonoylglycerol have been examined as well. Among the eicosanoids mediating cannabinoid actions are PGE2, 15-deoxy-Δ12,14-prostaglandin-J2, lipoxin A4, lipoxin B4, and leukotriene B4. Enzyme activities involved include monoacylglycerylipase, adenylatecyclase, phospholipase A2, cyclooxygenases-1, 2 and 5, lipoxygenases-12 and 15. Receptors involved include CB1, CB2 and the EP3 and EP3 prostanoid receptors. While not all cannabinoid activities can be accounted for, many are best explained by eicosanoid participation. The recent surge in interest in "medical marijuana" makes understanding mechanisms of cannabinoid actions particularly important.

PMID:
31104784
DOI:
10.1016/j.bmc.2019.05.018

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center